01 January 2008
Comparison of tacrolimus levels obtained with twice-daily administration formulation (Prograf®) and with once-daily formulation (Advagraf®)
M. T. Rabuñal Ãlvarez, E. Fernández Gabriel, M. Outeda MacÃas, I. MartÃn HerranzAnn Transplant 2008; 13(1): 38-38 :: ID: 880199
Abstract
Background: To compare tacrolimus levels before and after change from conventional formulation (Prograf[sup]®)[/sup] to extend-release formulation (Advagraf[sup]®[/sup]).
Material/Methods: 100% of transplanted patients were treated with Prograf[sup]® [/sup]and change to Advagraf[sup]®[/sup] during January-May/2008. Data that was taken into account was: sex, age, type and date of transplantation (computer application Gestión Documental®), pharmacokinetic data (computer program Openlab[sup]®)[/sup]. C[sub]min[/sub] determinations by whole-blood enzyme immunoassay on IM[sub]X [/sub]analyzer (Abbott). Concentrations comparison was done by the Wilcoxon's test.
Results: There were 31patients (20 males), of an average age of 53.8±14.4 years, who were transplanted between August/1999-March/2008 (22/kidney, 6/liver, 2/lung). Before the change, Prograf[sup]®'[/sup]s average dose was 4.53±3.3 mg/day and average C[sub]min[/sub] =8.597±4.99 ng/mL. In 13 patients, with a C[sub]min-Prograf®[/sub] =7.438 ng/mL, clinicians kept the same dose when they change to new formulation, obtaining a [sub]Cmin-Advagraf®[/sub] =5.054±1.42 ng/mL; it suppose a decrease of 30,68% (p=0.001). In the rest of patients the dose does not remain during conversion: in 10 patients, with a Cmin Prograf® =6.09±2.59 ng/mL, they increased dose and a C[sub]min-Advagraf®[/sub] = 5.92±2.88 ng/mL was reached, and in 8 patients, with a C[sub]min Prograf®[/sub] =13.61±7.19 ng/mL, they diminished dose and a C[sub]min-Advagraf®[/sub] =6.56±3.47 ng/mL was obtained. C[sub]min-Advagraf®[/sub] were minor than C[sub]min-Prograf®[/sub] in all cases.
Conclusions: Clinicians do 1:1 dosage conversion, because the same behavior is expected for both formulations. They only change dose to try to modify previous concentrations. By blood levels monitoring, we observed that, in all cases, concentrations obtained with Advagraf[sup]®[/sup] were minor than with Prograf[sup]®[/sup]. This decrease, notably superior to what it is described in bibliography, presents a clinical relevancy which does necessary a confirmation by the AUC profiles comparison for both formulations.
Keywords: Barrett’s Oesophagus, Columnar mucosa, Cytocheratin 7, p53, CDX2, Tacrolimus, Columnar mucosa
In Press
07 Mar 2024 : Original article
Outcomes of Renal Transplantation in ANCA-Associated VasculitisAnn Transplant In Press; DOI: 10.12659/AOT.943433
08 Mar 2024 : Original article
Association of Coronary Calcium Score on Cardiac PET During Pre-Kidney Transplant Assessment with Persisten...Ann Transplant In Press; DOI: 10.12659/AOT.943532
14 Mar 2024 : Original article
Impact of Blood Products Transfusion on Patients in the Immediate Post-Lung Transplant Period: A Cohort StudyAnn Transplant In Press; DOI: 10.12659/AOT.943652
14 Mar 2024 : Case report
Treatment of Cavernous Transformation of Portal Vein Caused by Hepatic Cystic Echinococcosis Using Ex Vivo ...Ann Transplant In Press; DOI: 10.12659/AOT.942358
Most Viewed Current Articles
05 Apr 2022 : Original article
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
12 Jan 2022 : Original article
Risk Factors for Developing BK Virus-Associated Nephropathy: A Single-Center Retrospective Cohort Study of ...DOI :10.12659/AOT.934738
Ann Transplant 2022; 27:e934738
22 Nov 2022 : Original article
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
15 Mar 2022 : Case report
Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...DOI :10.12659/AOT.935860
Ann Transplant 2022; 27:e935860